Related Experiment Videos
A public-private partnership for malaria control: lessons from the Malarone Donation Programme
A B O Olukayode Oyediran1, Edward M Ddumba, Samuel A Ochola
1Malarone Donation Programme Africa, Nairobi, Kenya.
Bulletin of the World Health Organization
|December 10, 2002
Summary
The Malarone Donation Programme improved malaria diagnosis and management in pilot sites. However, using Malarone as a second-line treatment was inefficient, highlighting the need for community-level malaria treatment strategies.
Area of Science:
- Global Health
- Infectious Diseases
- Malariology
Background:
- Malaria remains a significant global health challenge.
- Glaxo Wellcome initiated the Malarone Donation Programme (MDP) in 1997 to combat malaria.
- The MDP aimed to provide Malarone, an antimalarial drug, to reduce the global burden of the disease.
Purpose of the Study:
- To develop and evaluate a sustainable donation strategy for Malarone in Kenya and Uganda.
- To assess the controlled and appropriate use of Malarone in targeted populations.
- To improve malaria diagnosis and management at pilot sites.
Main Methods:
- Eight pilot sites in Kenya and Uganda were established.
- The program targeted patients with acute uncomplicated Plasmodium falciparum malaria resistant to first-line treatments.
- Directly observed treatment with Malarone was administered to eligible patients.
Main Results:
- Out of 161,079 diagnosed malaria cases, 1101 (0.68%) received Malarone.
- The MDP positively impacted malaria diagnosis and management at the pilot sites.
- Providing Malarone as a second-line drug at district hospitals proved resource-inefficient.
Conclusions:
- The Malarone Donation Programme demonstrated benefits in improving malaria care locally.
- Resource allocation for Malarone as a second-line treatment requires re-evaluation for efficiency.
- Addressing malaria treatment challenges at the community level should be a high priority.